Before revision: Phase III trials were published in January 2023 on CVO+ resulted in a significantly higher rate of treatment success and that it was effective for the treatment of mild-to-moderate forms of COVID-19
After revision: A Phase III clinical trial for CVO+, conducted in Madagascar, was published in January 2023 , claiming a significantly higher rate of treatment success and that CVO+ was effective for the treatment of mild-to-moderate forms of COVID-19